Evidence map›Paper›PMID 36533912›Full record

ArticleMicrobiology spectrum2023

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.

Maria G Nava, Félix Calderón, Elena Fernández, Lluis Ballell, Paul Bamborough, Sumiti Vinayak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. TKL family kinases in human apicomplexan pathogens.Molecular and biochemical parasitology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Maria G NavaDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Félix CalderónGlobal Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Elena FernándezGlobal Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Lluis BallellGlobal Health, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Paul BamboroughMolecular Design, GlaxoSmithKline, Stevenage, Herts, United Kingdom.
Sumiti VinayakDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.ORCID 0000-0003-4549-6268
GlaxoSmithKline (Spain) · ESUniversity of Illinois Urbana-Champaign · USGlaxoSmithKline (United Kingdom) · GB

Funding

Molecular signaling mechanisms controlling Cryptosporidium proliferation and developmentR01AI150961 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ALAM, SUMITI VINAYAK · 2021 to 2025
$1.9M
Tool for studying essential gene function in Cryptosporidium parvumR21AI142380 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ALAM, SUMITI VINAYAK · 2019 to 2020
$427k
NIAID NIH HHS R01 AI150961NIAID NIH HHS R21 AI142380
6 · The paper itself

Abstract

The protozoan parasite

Indexed as

CryptosporidiosisCryptosporidiumCryptosporidium parvumAnimalsChildChild, PreschoolHumansTyrosine Kinase InhibitorsTyrosine Kinase Inhibitorsanti-parasitic compoundscryptosporidiosisCryptosporidiumkinase library screeningprotozoan parasitetyrosine kinase inhibitors

Identifiers

PMID36533912
PMCPMC9927415
OpenAlexW4311930855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.